Biomedical and Lifestyle Diseases (BioLED) Unit, College of Health and Biomedicine, Victoria University, Melbourne, Victoria 3021, Australia.
Complement Ther Med. 2013 Jun;21(3):180-9. doi: 10.1016/j.ctim.2013.01.004. Epub 2013 Feb 23.
Central obesity is a key component of metabolic syndrome and it is often associated with other risk factors such as dyslipidemia, elevated plasma glucose levels and elevated blood pressure (BP). In this pilot study, the effect of Caralluma fimbriata (an edible succulent) extract in combination with controlled dietary intake and physical activity on these risk factors was assessed in overweight and obese Australian subjects.
This was a randomised, double blind placebo controlled clinical trial. Forty-three adults aged 29-59 years were recruited. The eligibility criteria included a Body Mass Index (BMI) >25 kg/m(2), or a waist circumference >94 cm (male), >80 cm (female). Thirty-three participants completed the 12-week study at Victoria University Nutritional Therapy Clinic. Participants were randomly assigned into two groups. C. fimbriata extract and placebo were orally administered as 500 mg capsules twice daily (1 g/day) and dietary intake and exercise were monitored weekly.
The results of thirty-three participants (experimental group, n = 17; placebo group n = 16) were analysed. The primary outcome measure was the decline in waist circumference. By week 9, the experimental group had lost 5.7 cm, compared to only 2.8 cm loss in the placebo group (Difference: -2.890; 95% CI; -5.802 to 0.023). Post intervention, the experimental group had lost 6.5 cm compared to 2.6 cm loss in the placebo group (Difference: -3.847; 95% CI; -7.466 to 0.228). Waist to hip ratio (WHR) also improved significantly after 12 weeks intervention in the experimental group, with a total reduction of 0.03 being recorded compared to 0.01 increase in the placebo group (Difference: -0.033; 95% CI; -0.064 to -0.002). There was also a significant decline in the palatability (visual appeal, smell, taste) of the test meal and sodium intake in the experimental group at week 12 (p < 0.05). In addition a significant reduction in body weight, BMI, hip circumference, systolic BP, HR, triglyceride levels, total fat and saturated fat intake within both groups was observed following the intervention period (p < 0.05).
Supplementation with C. fimbriata extract whilst controlling overall dietary intake and physical activity may potentially play a role in curbing central obesity, the key component of metabolic syndrome. Controlling dietary intake and exercise improved body weight and favourably influenced the metabolic risk profile.
中心性肥胖是代谢综合征的一个关键组成部分，它通常与其他危险因素相关，如血脂异常、血糖水平升高和血压升高。在这项初步研究中，评估了食用 Caralluma fimbriata（一种可食用的肉质植物）提取物结合控制饮食摄入和体育活动对超重和肥胖的澳大利亚受试者这些危险因素的影响。
这是一项随机、双盲、安慰剂对照的临床试验。招募了 43 名年龄在 29-59 岁的成年人。入选标准包括体重指数（BMI）>25 kg/m²，或腰围>94 cm（男性），>80 cm（女性）。33 名参与者在维多利亚大学营养治疗诊所完成了 12 周的研究。参与者被随机分为两组。C. fimbriata 提取物和安慰剂均口服，每天两次 500mg 胶囊（每天 1g），每周监测饮食摄入和运动情况。
分析了 33 名参与者（实验组，n=17；安慰剂组，n=16）的结果。主要结局测量指标是腰围的下降。到第 9 周，实验组腰围减少了 5.7cm，而安慰剂组仅减少了 2.8cm（差异：-2.890；95%CI；-5.802 至 0.023）。干预后，实验组腰围减少了 6.5cm，而安慰剂组减少了 2.6cm（差异：-3.847；95%CI；-7.466 至 0.228）。12 周干预后，实验组的腰臀比（WHR）也显著改善，总减少 0.03，而安慰剂组增加 0.01（差异：-0.033；95%CI；-0.064 至 -0.002）。实验组在第 12 周时还观察到试验餐的适口性（视觉吸引力、气味、味道）和钠摄入量显著下降（p<0.05）。此外，两组在干预期间均观察到体重、BMI、臀围、收缩压、心率、甘油三酯水平、总脂肪和饱和脂肪摄入量显著降低（p<0.05）。
在控制总体饮食摄入和体育活动的同时，补充 C. fimbriata 提取物可能在控制中心性肥胖（代谢综合征的关键组成部分）方面发挥作用。控制饮食摄入和运动改善了体重，并对代谢风险状况产生了有利影响。
